IL17A and psoriasis: In support of our human findings, the IMQ-induced mouse model of psoriasis also showed a downregulation of Eppk1. However, in contrast to the selective downregulation observed in human psoriasis, IMQ treatment led to broader suppression of multiple plakins, including Ppl, Evpl, and Dst. These differences may reflect species-specific immune responses or distinct cytokine environments; the IMQ model primarily activates the IL-17/IL-23 axis and lacks the chronic inflammation and complex immune milieu characteristic of human disease (van der Fits et al., 2009; Swindell et al., 2017).